The impact of perioperative CA19-9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma

J Surg Oncol. 2018 Mar;117(3):380-388. doi: 10.1002/jso.24856. Epub 2017 Sep 20.

Abstract

Backgrounds: Perioperative CA19-9 value in pancreato-biliary cancers has been recognized as a prognostic factor. Herein, we investigated survival differences and recurrence patterns after adjuvant chemoradiotherapy by perioperative CA19-9 change in surgically resected extrahepatic cholangiocarcinoma.

Methods: Patients were divided into those with preoperative normal CA19-9 (Group 1, n = 52), those with high preoperative and normalized postoperative CA19-9 (Group 2, n = 80), and those with both high pre- and postoperative CA19-9 (Group 3, n = 21).

Results: Depending on the group defined above, the 5-year overall survival (OS) (59.6%, 38.7%, and 9.5%, P < 0.001) and disease-free survival (55.8%, 31.2%, and 9.5%, P < 0.001) between the three groups differed. On multivariable analysis in patients other than group 1, poor prognosticators for OS were high postoperative CA19-9 (HR 2.26, P = 0.008) and N1 disease (HR 2.33, P = 0.001). Group 3, compared with group 2, showed higher distant metastasis rate, shorter disease-free interval, and higher CA19-9 at the time of recurrence.

Conclusions: Survival and recurrence patterns after adjuvant chemoradiotherapy are significantly affected by perioperative CA19-9 change. This may have important implications in patient selection for adjuvant chemoradiotherapy and clinical trial design.

Keywords: CA19-9; adjuvant chemoradiotherapy; extrahepatic cholangiocarcinoma.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • CA-19-9 Antigen / blood*
  • Chemoradiotherapy, Adjuvant
  • Cholangiocarcinoma / blood*
  • Cholangiocarcinoma / therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / blood
  • Perioperative Period
  • Retrospective Studies

Substances

  • CA-19-9 Antigen